Rini, Brian I <br/><br/>
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?  [electronic resource] 

 -  Expert review of anticancer therapy  Dec 2006 
 - 1753-60 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1744-8328 
<br/><br/><label>Standard No.: </label>10.1586/14737140.6.12.1753  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Agents--pharmacology<br/>Benzenesulfonates--therapeutic use<br/>Bevacizumab<br/>Carcinoma, Renal Cell--blood supply<br/>Case Management--trends<br/>Clinical Trials as Topic<br/>Combined Modality Therapy<br/>Cytokines--therapeutic use<br/>Humans<br/>Indoles--therapeutic use<br/>Kidney Neoplasms--blood supply<br/>Neovascularization, Pathologic--drug therapy<br/>Nephrectomy--methods<br/>Niacinamide--analogs & derivatives<br/>Phenylurea Compounds<br/>Pyridines--therapeutic use<br/>Pyrroles--therapeutic use<br/>Sirolimus--analogs & derivatives<br/>Sorafenib<br/>Sunitinib<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors